Increased risk of severe skin reactions with expectorants containing ambroxol or bromhexinePatients taking expectorants containing ambroxol or bromhexine have a small increased risk of severe skin reactions such as Stevens-Johnson syndrome.…
Anaesthetists campaign for pholcodine cough medicines to become prescription-only products Anaesthetists in Australia and New Zealand are campaigning for pholcodine-containing cough medicines to become prescription-only products.…
Redesigned aminoglycoside may eliminate risk of hearing loss Researchers have diminished the toxicity of the aminoglycoside sisomicin — which can cause hearing damage or loss — by altering its molecular structure.…
Interim results of stem cell treatment for multiple sclerosis show promise Stem cell treatment after high-dose immunosuppressive therapy could be an effective way to manage relapsing remitting multiple sclerosis.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Risk modelling study suggests aspirin’s harms outweigh benefits for younger women For most women, the long-term benefits of aspirin do not outweigh the increase in major gastrointestinal bleeding, say researchers.…
Ebola clinical trial suspended after volunteers complain of joint pains A phase I clinical trial of the fast-tracked Ebola vaccine VSV-ZEBOV has been halted in Switzerland because some trial participants developed mild joint pain.…
Pfizer offers settlement in class action over Parkinson’s drug CabaserCompany has offered to settle a class action brought by more than 150 patients in Australia who allege they were never warned about the side effects of treatment.…
Survey suggests US doctors are changing their prescribing habits for opioid drugsMany primary care physicians are less likely to prescribe opioids now than a year ago, according to a survey of US doctors.…
Review examines link between paracetamol use and asthma Researchers observed a positive association between paracetamol use in pregnancy and asthma but were unable to find sufficient evidence to support a change in guidance.…